Swedbank
BMRN icon

Swedbank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Swedbank’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$88.6M Buy
1,476,737
+161,950
+12% +$10.2M 0.08% 173
2026
Q2 		$75.2M Buy
1,314,787
+522,600
+66% +$28.6M 0.06% 201
2026
Q1 		$44.8M Sell
792,187
-4,550
-0.6% -$265K 0.05% 238
2025
Q4 		$47.4M Buy
796,737
+329,794
+71% +$18M 0.05% 232
2025
Q3 		$25.3M Buy
466,943
+35,000
+8% +$2M 0.03% 344
2025
Q2 		$23.7M Buy
431,943
+2,100
+0.5% +$124K 0.03% 333
2025
Q1 		$30.4M Sell
429,843
-2,279
-0.5% -$153K 0.04% 282
2024
Q4 		$28.4M Buy
432,122
+43,593
+11% +$2.92M 0.03% 289
2024
Q3 		$27.3M Buy
388,529
+100,000
+35% +$8.36M 0.03% 286
2024
Q2 		$23.8M Sell
288,529
-7,600
-3% -$633K 0.03% 290
2024
Q1 		$25.9M Sell
296,129
-170,100
-36% -$15.2M 0.04% 280
2023
Q4 		$45M Sell
466,229
-40,800
-8% -$3.61M 0.07% 194
2023
Q3 		$44.9M Hold
507,029
– – 0.08% 185
2023
Q2 		$43.9M Hold
507,029
– – 0.07% 200
2023
Q1 		$49.3M Buy
507,029
+59,200
+13% +$6.14M 0.1% 173
2022
Q4 		$46.3M Buy
447,829
+26,900
+6% +$2.53M 0.1% 185
2022
Q3 		$35.7M Sell
420,929
-108,190
-20% -$9.6M 0.08% 198
2022
Q2 		$43.8M Buy
529,119
+24,661
+5% +$1.96M 0.1% 182
2022
Q1 		$38.9M Buy
504,458
+183,493
+57% +$15.4M 0.07% 226
2021
Q4 		$28.6M Sell
320,965
-15,058
-4% -$1.24M 0.05% 278
2021
Q3 		$26M Buy
336,023
+192,144
+134% +$15.2M 0.05% 289
2021
Q2 		$12M Hold
143,879
– – 0.02% 446
2021
Q1 		$10.9M Buy
+143,879
New +$11.8M 0.02% 451

Other funds holding BMRN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
ARGA Investment Management
ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Swedbank's BMRN Position: Q3 2026 in Review

Swedbank increased its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q3 2026, buying an estimated $10.2M and bringing the position to 1,476,737 shares worth $88.6M. The position accounts for 0.08% of the portfolio, ranked #173.

Swedbank first reported a position in BMRN in Q1 2021 and has held it in 23 quarters since. 249 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Swedbank held 1,476,737 shares of BioMarin Pharmaceuticals worth $88.6M as of Q3 2026.
  • Swedbank bought 161,950 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $10.2M.
  • BioMarin Pharmaceuticals made up 0.08% of Swedbank's portfolio in Q3 2026, its #173 holding.
  • Swedbank first reported a position in BioMarin Pharmaceuticals in Q1 2021 and has held it in 23 quarters since.
  • 249 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Swedbank's 13F filing for Q3 2026, filed 27 Oct 2026.